Genomic Profiling of Human Carcinomas to Identify Aberrant Signaling Pathways
Using patient-derived normal tissue and tumor tissue, Dr. Copland's Cancer Biology and Translational Oncogenomics Laboratory performs whole-genome-wide expression analysis to identify genes aberrantly regulated in human cancers.
These aberrantly expressed genes can then be validated by quantitative polymerase chain reaction (QPCR) and immunohistochemistry (IHC).
Using human cell lines, identified genes are either silenced or re-expressed, establishing transgenic cell lines to determine the role of the gene in tumor survival, proliferation, invasion and metastasis.
Identification of aberrant signaling pathways will allow for an understanding of the molecular pathways governing each cancer subtype.
Using this information provides a rational approach in designing combinatorial molecular-targeted therapies with the potential for personalized diagnosis and treatment.
Review poster presentations related to Dr. Copland's research on RhoB and FoxO3a signaling in anaplastic thyroid carcinoma (PDF files requiring Adobe Reader):